Stromal Cell Derived Factor-1 and Long-Term Prognosis in Acute Coronary Syndrome

Peiró, Óscar M.; Farré, Núria; Cediel, Germán; Bonet, Gil; Rojas, Sergio; Quintern, Verónica; Bardajı́, Alfredo

doi:10.2217/bmm-2019-0133

Cited by 3 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies assessing circulating SDF-1α levels as a prognostic indicator in CAD patients have shown that its elevation was associated with increased risk of adverse cardiovascular events, including myocardial infarction and CV mortality in chronic coronary syndrome patients and ACS patients [ 12 – 14 ]. Conversely, other studies have reported a reduction in circulating SDF-1α in patients with myocardial infarction [ 38 ], and with stable and unstable angina compared to healthy controls [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

“…The chemokine stromal cell derived factor-1α (SDF-1α/CXCL12) is a CXC chemokine with chemotactic effects on CXCR4/CXCR7 (CXCR: CXC chemokine receptor) expressing progenitor cells [ 10 ] and is known to play beneficial roles in cardiomyocyte repair and ventricular remodelling [ 11 ]. The prognostic value of circulating SDF-1α levels has been previously evaluated in several studies in patients with CAD [ 12 – 14 ], most of which reported that an elevated level of total SDF-1α was significantly associated with increased risk of poor outcomes in patients with CAD. Moreover, previous studies have suggested that SDF-1α play a key role in the pathogenesis of T2DM [ 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated levels of plasma inactive stromal cell derived factor-1α predict poor long-term outcomes in diabetic patients following percutaneous coronary intervention

Chikata,

Iwata,

Miyosawa

et al. 2024

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background Since the complication of diabetes mellitus (DM) is a risk for adverse cardiovascular outcomes in patients with coronary artery disease (CAD), appropriate risk estimation is needed in diabetic patients following percutaneous coronary intervention (PCI). However, there is no useful biomarker to predict outcomes in this population. Although stromal cell derived factor-1α (SDF-1α), a circulating chemokine, was shown to have cardioprotective roles, the prognostic impact of SDF-1α in diabetic patients with CAD is yet to be fully elucidated. Moreover, roles of SDF-1α isoforms in outcome prediction remain unclear. Therefore, this study aimed to assess the prognostic implication of three forms of SDF-1α including total, active, and inactive forms of SDF-1α in patients with DM and after PCI. Methods This single-center retrospective analysis involved consecutive patients with diabetes who underwent PCI for the first time between 2008 and 2018 (n = 849). Primary and secondary outcome measures were all-cause death and the composite of cardiovascular death, non-fatal myocardial infarction, and ischemic stroke (3P-MACE), respectively. For determining plasma levels of SDF-1α, we measured not only total, but also the active type of SDF-1α by ELISA. Inactive isoform of the SDF-1α was calculated by subtracting the active isoform from total SDF-1α. Results Unadjusted Kaplan–Meier analyses revealed increased risk of both all-cause death and 3P-MACE in patients with elevated levels of inactive SDF-1α. However, plasma levels of total and active SDF-1α were not associated with cumulative incidences of outcome measures. Multivariate Cox hazard analyses repeatedly indicated the 1 higher log-transformed inactive SDF-1α was significantly associated with increased risk of all-cause death (hazard ratio (HR): 2.64, 95% confidence interval (CI): 1.28–5.34, p = 0.008) and 3P-MACE (HR: 2.51, 95% CI: 1.12–5.46, p = 0.02). Moreover, the predictive performance of inactive SDF-1α was higher than that of total SDF-1α (C-statistics of inactive and total SDF-1α for all-cause death: 0.631 vs 0.554, for 3P-MACE: 0.623 vs 0.524, respectively). Conclusion The study results indicate that elevated levels of plasma inactive SDF-1α might be a useful indicator of poor long-term outcomes in diabetic patients following PCI. Trial registration: This study describes a retrospective analysis of a prospective registry database of patients who underwent PCI at Juntendo University Hospital, Tokyo, Japan (Juntendo Physicians’ Alliance for Clinical Trials, J-PACT), which is publicly registered (University Medical Information Network Japan—Clinical Trials Registry, UMIN-CTR 000035587).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Elevated levels of plasma inactive stromal cell derived factor-1α predict poor long-term outcomes in diabetic patients following percutaneous coronary intervention

Chikata,

Iwata,

Miyosawa

et al. 2024

Cardiovasc Diabetol

View full text Add to dashboard Cite

show abstract

“…As an inflammatory chemokine, SDF-1 can induce the expression of tumor necrosis factor-α (TNF-α), leading to the apoptosis of cardiomyocytes [29]. In addition, SDF-1 can aggravate cardiac remodeling and worsen cardiac function by enhancing the proliferation of cardiac fibroblasts and collagen production [30]. Correspondingly, plasma SDF-1 levels can serve as a predictor of myocardial infarction (MI) in patients with chronic kidney disease (CKD) [31].…”

Section: Discussionmentioning

confidence: 99%

Association of serum stromal cell-derived factor 1 levels with EZSCAN score and its derived indicators in patients with type 2 diabetes

Liu

Hua

Zhu

et al. 2022

Endocrine Connections

View full text Add to dashboard Cite

Background: The aim of the study was to explore whether plasma stromal cell-derived factor-1 (SDF-1) levels are associated with the EZSCAN score and its derived indicators in patients with type 2 diabetes (T2D). Methods: From July 2020 to December 2020, a total of 253 patients with T2D were consecutively recruited. Serum SDF-1 levels were measured by sandwich ELISA. EZSCAN test was applied to evaluate sudomotor function of each patient, and based on the results, EZSCAN score, cardiac autonomic neuropathy risk score (CANRS) and cardiovascular risk score (CVDRS) were calculated by particular algorithms. In addition, other relevant clinical data were also collected. Results: With increasing tertiles of serum SDF-1 levels, the CANRS and CVDRS significantly increased (both p for trend < 0.001), while the EZSCAN score significantly decreased (p for trend < 0.001). Moreover, serum SDF-1 levels were significantly and positively correlated with the CANRS and CVDRS (r = 0.496 and 0.510, respectively, both p < 0.001), and negatively correlated with the EZSCAN score (r = -0.391, p < 0.001). Furthermore, multivariate linear regression analyses were constructed, and after adjusting for other clinical covariates, serum SDF-1 levels were independently responsible for EZSCAN score (β = 0.662, t = -3.679, p < 0.001), CANRS (β = 0.334, t = 5.110, p < 0.001) and CVDRS (β = 0.191, t = 4.983, p = 0.003). Conclusions: SDF-1 levels in serum were independently associated with the EZSCAN score and its derived indicators, such as CANRS and CVDRS in patients with T2D.

show abstract

“…Chang et al (11) first reported that the higher serum CXCL12 level predicted 30-day major adverse clinical outcomes in patients with AMI. Thereafter, other studies also reported the correlation between higher blood CXCL12 levels and increased risk of future adverse clinical outcomes in patients with CAD (12)(13)(14). In contrast, negative or even opposite results were also reported (16).…”

Section: Forest Plot Of the Association Between Cxcl Level As Categor...mentioning

confidence: 94%

“…Chang et al first reported that a higher serum CXCL12 level positively predicted 30-day major adverse clinical outcomes in patients with acute myocardial infarction (AMI) (11). Thereafter, several studies supported the positive correlation between higher blood CXCL12 levels and increased risk of future (both short and long terms) adverse clinical outcomes in patients with CAD (12)(13)(14). However, negative or even opposite results were also reported, which found no significant correlation between blood CXCL12 levels and CAD prognosis (15), or even higher serum CXCL12 levels predicting lower future cardiovascular events in patients with CAD (16).…”

Section: Introductionmentioning

confidence: 95%

The role of blood CXCL12 level in prognosis of coronary artery disease: A meta-analysis

Zhang

Ding

Fan

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

ObjectiveThe role of C-X-C motif chemokine 12 (CXCL12) in atherosclerotic cardiovascular diseases (ASCVDs) has emerged as one of the research hotspots in recent years. Studies reported that the higher blood CXCL12 level was associated with increased major adverse cardiovascular events (MACEs), but the results were inconsistent. The objective of this study was to clarify the prognostic value of the blood CXCL12 level in patients with coronary artery disease (CAD) through meta-analysis.MethodsAll related studies about the association between the blood CXCL12 level and the prognosis of CAD were comprehensively searched and screened according to inclusion criteria and exclusion criteria. The quality of the included literature was evaluated using the Newcastle-Ottawa Scale (NOS). The heterogeneity test was conducted, and the pooled hazard risk (HR) or the odds ratio (OR) with a 95% confidence interval (CI) was calculated using the fixed-effect or random-effects model accordingly. Publication bias was evaluated using Begg's funnel plot and Egger's test. Sensitivity analysis and subgroup analysis were also conducted.ResultsA total of 12 original studies with 2,959 CAD subjects were included in the final data combination. The pooled data indicated a significant association between higher CXCL12 levels and MACEs both in univariate analysis (HR 5.23, 95% CI 2.48–11.04) and multivariate analysis (HR 2.53, 95% CI 2.03–3.16) in the CXCL12 level as the category variable group. In the CXCL12 level as the continuous variable group, the result also indicated that the higher CXCL12 level significantly predicted future MACEs (multivariate OR 1.55, 95% CI 1.02–2.35). Subgroup analysis of the CXCL12 level as the category variable group found significant associations in all acute coronary syndrome (ACS) (univariate HR 9.72, 95% CI 4.69–20.15; multivariate HR 2.47, 95% CI 1.79–3.40), non-ACS (univariate HR 2.73, 95% CI 1.65–4.54; multivariate HR 3.49, 95% CI 1.66–7.33), Asian (univariate HR 7.43, 95% CI 1.70–32.49; multivariate HR 2.21, 95% CI 1.71–2.85), Caucasian (univariate HR 3.90, 95% CI 2.73–5.57; multivariate HR 3.87, 95% CI 2.48–6.04), short-term (univariate HR 9.36, 95% CI 4.10–21.37; multivariate HR 2.72, 95% CI 1.97–3.76), and long-term (univariate HR 2.86, 95% CI 1.62–5.04; multivariate HR 2.38, 95% CI 1.76–3.22) subgroups. Subgroup analysis of the CXCL12 level as the continuous variable group found significant associations in non-ACS (multivariate OR 1.53, 95% CI 1.23–1.92), Caucasian (multivariate OR 3.83, 95% CI 1.44–10.19), and long-term (multivariate OR 1.62, 95% CI 1.37–1.93) subgroups, but not in ACS (multivariate OR 1.36, 95% CI 0.67–2.75), Asian (multivariate OR 1.40, 95% CI 0.91–2.14), and short-term (multivariate OR 1.16, 95% CI 0.28–4.76) subgroups. No significant publication bias was found in this meta-analysis.ConclusionThe higher blood CXCL12 level is associated with increased MACEs in patients with CAD, and the blood CXCL12 level may serve as an important prognostic index for CAD. Integrating the blood CXCL12 level into CAD risk assessment tools may provide more comprehensive messages for evaluating and managing patients with CAD.

show abstract

Stromal Cell Derived Factor-1 and Long-Term Prognosis in Acute Coronary Syndrome

Cited by 3 publications

References 40 publications

Elevated levels of plasma inactive stromal cell derived factor-1α predict poor long-term outcomes in diabetic patients following percutaneous coronary intervention

Elevated levels of plasma inactive stromal cell derived factor-1α predict poor long-term outcomes in diabetic patients following percutaneous coronary intervention

Association of serum stromal cell-derived factor 1 levels with EZSCAN score and its derived indicators in patients with type 2 diabetes

The role of blood CXCL12 level in prognosis of coronary artery disease: A meta-analysis

Contact Info

Product

Resources

About